GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced ...

Nonalcoholic fatty liver disease is the most common liver disease in America. If you have any of these fatty liver symptoms ...

Pharma Two B Ltd. (“Pharma Two B”), a late-clinical stage company that is developing P2B001, an innovative combination ...

Nonalcoholic fatty liver disease (NAFLD) and its progressive form, nonalcoholic steatohepatitis (NASH) are the most common causes of chronic liver disease in industrialized countries. NAFLD has ...

CONSHOHOCKEN, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: MDGL) today announced that the company will participate in fireside chats at three upcoming investor conferences: UBS Global Healthcare ...

CONSHOHOCKEN, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for nonalcoholic steatohepatitis (NASH)/metabolic ...

A new study published in the Journal of Hepatology Reports and conducted by a team of researchers from the Hebrew University ...

This article explores how eating junk food raises the risk of fatty liver diseases, examines symptoms, and highlights ...

(ETNB – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst on November 7. Analyst Thomas Smith ...

Namodenoson has already shown potential in other significant indications, such as hepatocellular carcinoma (HCC) and non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH), ...

Learn about HMGB1's crucial role in liver diseases, its pathways and therapeutic potential that can treat liver diseases.